Bellerophon Therapeutics Stock Gross Profit
Bellerophon Therapeutics fundamentals help investors to digest information that contributes to Bellerophon Therapeutics' financial success or failures. It also enables traders to predict the movement of Bellerophon Pink Sheet. The fundamental analysis module provides a way to measure Bellerophon Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Bellerophon Therapeutics pink sheet.
Bellerophon |
Bellerophon Therapeutics Company Gross Profit Analysis
Bellerophon Therapeutics' Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
CompetitionAccording to the company disclosure, Bellerophon Therapeutics reported 0.0 of gross profit. This is 100.0% lower than that of the Health Care Equipment & Supplies sector and 100.0% lower than that of the Health Care industry. The gross profit for all United States stocks is 100.0% higher than that of the company.
Bellerophon Gross Profit Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bellerophon Therapeutics' direct or indirect competition against its Gross Profit to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Bellerophon Therapeutics could also be used in its relative valuation, which is a method of valuing Bellerophon Therapeutics by comparing valuation metrics of similar companies.Bellerophon Therapeutics is currently under evaluation in gross profit category among its peers.
Bellerophon Fundamentals
| Return On Equity | -1.39 | |||
| Return On Asset | -0.6 | |||
| Profit Margin | (2.20) % | |||
| Operating Margin | (2.48) % | |||
| Current Valuation | (9.32 M) | |||
| Shares Outstanding | 12.23 M | |||
| Shares Owned By Insiders | 3.97 % | |||
| Shares Owned By Institutions | 45.08 % | |||
| Number Of Shares Shorted | 90.45 K | |||
| Price To Earning | 5.33 X | |||
| Price To Book | 1.05 X | |||
| EBITDA | (22.39 M) | |||
| Net Income | (19.83 M) | |||
| Cash And Equivalents | 16.33 M | |||
| Cash Per Share | 1.71 X | |||
| Total Debt | 203 K | |||
| Debt To Equity | 0.05 % | |||
| Current Ratio | 3.12 X | |||
| Book Value Per Share | 0.46 X | |||
| Cash Flow From Operations | (17.77 M) | |||
| Short Ratio | 1.26 X | |||
| Earnings Per Share | (0.34) X | |||
| Target Price | 2.0 | |||
| Number Of Employees | 18 | |||
| Beta | 0.55 | |||
| Market Capitalization | 1.25 M | |||
| Total Asset | 7.93 M | |||
| Retained Earnings | (252.08 M) | |||
| Working Capital | 2.16 M | |||
| Current Asset | 29.45 M | |||
| Current Liabilities | 8.07 M | |||
| Z Score | -49.75 | |||
| Net Asset | 7.93 M |
Currently Active Assets on Macroaxis
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Other Consideration for investing in Bellerophon Pink Sheet
If you are still planning to invest in Bellerophon Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Bellerophon Therapeutics' history and understand the potential risks before investing.
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal |